Business
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI ...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results\nRobust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications Well-capitalized into H2 2028, beyond key catalysts with over $140 million cash VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the first quarter of 2026. \"The clinical data reported this quarter further reinforces the potential for EP-104GI to become an important new treatment for Eosinophilic Esophagitis (EoE),” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “With the capital from the recent financing, we are excited to continue development of EP-104GI in EoE and accelerate additional clinical programs in new indications within the GI field, where we believe that EP-104GI has the opportunity to work due to the Diffusphere’s ability to provide hyper-targeted delivery into diseased areas over a long period of time without the typical systemic exposure profile.” Recent Operational and Financial Highlights On January 8, 2026, the Company announced positive tissue health data from its ongoing RESOLVE trial in EoE demonstrating near-complete improvement on biopsy.On February 20, 2026, the Company announced the closing of a public offering of Common Shares (the “Offering”). The Company issued 7,607,145 Common Shares at a price of $7.00 per Common Share for gross proceeds of approximately $63.2 million which included the issuance of 1,178,571 Common Shares upon full exercise of the option to purchase additional shares granted to the underwriters, and 1,428,571 Pre-Funded Warrants at a price of $6.99999 per Pre-Funded Warrant.On March 17, 2026, the Company announced six-month symptom data from the highest dose cohort in its ongoing Phase 1b/2a RESOLVE trial in EoE.On April 21, 2026, the Company announced positive nine-month tissue health and symptom data from the highe...